OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$10.62 USD
0.00 (0.00%)
Updated May 6, 2024 04:00 PM ET
After-Market: $10.60 -0.02 (-0.19%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.62 USD
0.00 (0.00%)
Updated May 6, 2024 04:00 PM ET
After-Market: $10.60 -0.02 (-0.19%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
Zacks News
OptimizeRx Corp. (OPRX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -60% and 18.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Inc. (PTC) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
PTC Inc. (PTC) delivered earnings and revenue surprises of -9.35% and 2.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Manhattan Associates (MANH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Manhattan Associates (MANH) delivered earnings and revenue surprises of 30.19% and 6.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Moves 8.9% Higher: Will This Strength Last?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sapiens (SPNS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Sapiens (SPNS) delivered earnings and revenue surprises of 14.81% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 22.22% and 1.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Misses Q3 Earnings Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -30.77% and 8.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 42.86% and 10.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OptimizeRx Corp. (OPRX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 200.00% and 8.79%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Mar 17, 2021
by Zacks Equity Research
Companies in the news are: JBL, CNF, OPRX, MRNA
OptimizeRx Corp. (OPRX) Soars 12%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 6.67% and 2.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx's (OPRX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in OptimizeRx (OPRX).
OptimizeRx (OPRX) Looks Good: Stock Adds 9.5% in Session
by Zacks Equity Research
OptimizeRx (OPRX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
OptimizeRx's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in OptimizeRx.
Zacks.com featured highlights include: Digital Turbine, Perion, Controladora Vuela, OptimizeRx and Eldorado Gold
by Zacks Equity Research
Zacks.com featured highlights include: Digital Turbine, Perion, Controladora Vuela, OptimizeRx and Eldorado Gold